ArticleJournal of medicinal chemistry2020
Identification and Development of a New Positron Emission Tomography Ligand 4-(2-Fluoro-4-[
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Radiosynthesis and Preclinical Evaluation of a NovelACS medicinal chemistry letters · 2026Article
- Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2.ACS pharmacology & translational science · 2024Article
- Synthesis and Characterization of 5-(2-Fluoro-4-[Journal of medicinal chemistry · 2022Article
- Upregulation of Striatal Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Rats with Excessive Glutamate Release Induced by N-Acetylcysteine.Neurotoxicity research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Tomoteru YamasakiDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Xiaofei ZhangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Katsushi KumataDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Yiding ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Xiaoyun DengDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.
Masayuki FujinagaDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Zhen ChenDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0002-6289-4332
Wakana MoriDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Kuan HuDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0003-2448-2254
Hidekatsu WakizakaDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Akiko HatoriDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Lin XieDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Masanao OgawaDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Nobuki NengakiDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
Richard VanDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.
Yihan ShaoDepartment of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States.ORCID 0000-0001-9337-341X
Douglas J ShefflerCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Nicholas D P CosfordCancer Metabolism and Signaling Networks Program and Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
Steven H LiangDivision of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0003-1413-6315
Ming-Rong ZhangDepartment of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.ORCID 0000-0002-3001-9605
National Institutes for Quantum Science and Technology · JPHarvard University · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of Oklahoma · US
Funding
Lead optimization of Novel mGlu2 Negative Allosteric ModulatorsR01MH106865 · NIMH · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI COSFORD, NICHOLAS DAVID, DER-AVAKIAN, ANDRE · 2016 to 2018
$2.5MPET ligand development for mGlu2 based on negative allosteric modulatorsR01MH117125 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2018 to 2020
$1.6MNIMH NIH HHS R01 MH106865NIMH NIH HHS R01 MH117125
Abstract
Metabotropic glutamate receptor 2 (mGlu
Indexed as
AnimalsATP Binding Cassette Transporter, Subfamily G, Member 2AutoradiographyBrainCarbon RadioisotopesCell LineHumansLigandsMaleMiceMice, KnockoutMolecular ImagingMolecular StructureOrgan SpecificityPositron-Emission TomographyRats, Sprague-DawleyAbcg2 protein, mouseATP Binding Cassette Transporter, Subfamily G, Member 2Carbon RadioisotopesLigandsmetabotropic glutamate receptor 2Receptors, Metabotropic Glutamate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.